Comparison of Acadia Pharmaceuticals and C4 Therapeutics Highlights Valuation Differences
1 report, 1 independent
Updated Oct 19
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
A comparison of Acadia Pharmaceuticals and C4 Therapeutics revealed differences in financial metrics. Acadia Pharmaceuticals has higher top-line revenue and earnings per share than C4 Therapeutics. C4 Therapeutics trades at a lower price-to-earnings ratio, while Acadia Pharmaceuticals has higher institutional ownership at 96.7% compared to C4 Therapeutics' 78.8%.
From tickerreport.com
Why it matters
The comparison highlights differing risk profiles and valuations between the two companies. C4 Therapeutics has a beta of 3.07, suggesting its share price is 207% more volatile than the S&P 500, while Acadia Pharmaceuticals has a beta of 0.88.
From tickerreport.com
Who's involved
- Acadia PharmaceuticalsPharmaceutical company that is a subject of the comparison
- CitigroupInvestment bank that may influence financial ratings
- Morgan StanleyInvestment bank that may influence financial ratings
- Bank of AmericaMultinational banking corporation that provides financial ratings
- Royal Bank of CanadaFinancial institution that may influence financial ratings
- Securities and Exchange CommissionGovernment agency with which Acadia Pharmaceuticals must file regarding investment transparency
- European Medicines AgencyRegulatory authority that reviews Acadia's drug applications for European market access
- Norges BankCentral bank that is currently acquiring shares in Acadia Pharmaceuticals
Keep exploring
The entities involved
-
Acadia Pharmaceuticals
Pharmaceutical company, which developed Nuplazid, based in San Diego, California.